Nevertheless, we speculate that the fraction of STYK1 released from EGFR upon its inhibition is probably the STYK1 sub-population that contributes the most to the drug tolerance mechanisms to EGFR TKI in NSCLC cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.